Protalix BioTherapeutics (PLX) Announces Third Quarter 2025 Financial And Business Earnings Results

Protalix BioTherapeutics, Inc. (PLX) today announced its financial results for the recent quarter, revealing a diluted earnings per share of $0.03, which fell short of analysts’ expectations by $0.025. The company reported revenue of $17.85 million, slightly missing the estimated $17.88 million by $34,000. Despite the miss on both earnings and revenue, Protalix continues to navigate the challenges of the biopharmaceutical landscape.

Key Highlights:

• Protalix BioTherapeutics reported total revenues of $43.6 million for the first nine months of 2025, a 24% increase compared to the same period in 2024.
• Third-quarter revenues were $17.9 million, reflecting a slight decrease of 1% year-over-year.
• The company is excited about its PRX-115 candidate for uncontrolled gout, planning to initiate a phase 2 clinical trial later this year.
• An Investigational New Drug (IND) application for PRX-115 was submitted and became effective following the FDA’s review.
• The company is collaborating with Chiesi Global Rare Diseases on Elfabrio, which has a pending re-examination by the EMA regarding dosing regimens.

Protalix BioTherapeutics, Inc. reported its financial results for the third quarter of 2025, highlighting a total revenue of $43.6 million for the first nine months, marking a 24% increase from the previous year. CEO Dror Bashan noted that the revenues reflect the commercial success of their enzyme replacement therapies, despite a slight decrease in third-quarter revenues due to inventory management by partners like Chiesi and Pfizer. The company is particularly optimistic about its PRX-115 candidate for uncontrolled gout, which has shown promising results in early trials, and plans to advance to a phase 2 clinical trial soon.

In addition to the financial updates, Protalix is actively working on regulatory matters, including a recent IND submission for PRX-115 that has been approved by the FDA. The company is also addressing challenges related to its collaboration with Chiesi on Elfabrio, which is currently under review by the EMA for a new dosing regimen. Overall, Protalix is focused on expanding its product pipeline and enhancing its research and development efforts, with significant investments expected as they progress into more advanced clinical stages.

Protalix BioTherapeutics, Inc. (PLX) has experienced a rollercoaster ride in its stock price, with a notable decline of 10.08% over the past week, reflecting investor concerns amid a backdrop of fluctuating performance metrics. Despite this recent downturn, the stock has shown impressive resilience over the longer term, boasting a staggering 62.12% increase over the past year. This volatility can be attributed to the company’s unique position in the biotech sector, where its price-to-earnings ratio stands at a lofty 48.19, indicating high expectations for future growth. However, the revenue growth rate has been less than stellar, with a two-year compound annual growth rate (CAGR) of -4.17%, raising questions about sustainability. On a brighter note, Protalix has demonstrated a robust return on invested capital of nearly 49.37%, suggesting effective management of its resources. The company’s net profit margin of 4.73% also indicates that it is managing to turn a profit, albeit modestly. As investors weigh these mixed signals, the stock’s recent performance may prompt a reevaluation of its potential in the competitive biotech landscape. Overall, while the short-term price fluctuations may cause concern, the long-term growth trajectory remains a point of interest for investors.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.